Jaguar Health Receives $3 Million Payment From Future Pak for Mytesi and Canalevia-CA1 License Deal

-8.03% Post

Jaguar Animal Health, Inc.

JAGX

0.60

0.61

-8.03%

+1.33% Post

Jaguar Health said it received a $3 million payment from Future Pak after terminating the buy-back provision in their U.S. licensing agreement for Mytesi and Canalevia-CA1. The company said the termination allows Future Pak to continue commercializing Mytesi beyond five years, while Jaguar will continue manufacturing Mytesi and Canalevia-CA1 for Future Pak. Jaguar previously reported receiving $16 million in upfront non-dilutive capital in January 2026 upon entering the agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603030900ACCESSWRNAPR_____1142997) on March 03, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.